SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ZymoGenetics ZGEN
An SI Board Since February 2002
Posts SubjectMarks Bans Symbol
210 12 0 ZGEN
Emcee:  Mike McFarland Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
185<i>Read the release a little closer, they say "can" lead to deatSteve Lokness-8/20/2009
184Read the release a little closer, they say "can" lead to death. Itrkrw-8/20/2009
183<i>Marketing ploy.</i> Well sure. But if the deaths are real, whichSteve Lokness-8/20/2009
182<i>The history of this one is just beginning. Or do you mean the history oSteve Lokness-8/20/2009
181Marketing ploy.rkrw-8/20/2009
180Well, then, stay tuned. The history of this one is just beginning. Or do you mtuck-8/20/2009
179l would like to know the history of this petition; <i>ZymoGenetics SubmitSteve Lokness-8/20/2009
178Conference call on Lupus, which includes Dr. Hilson and atacicept, but which is tuck-7/25/2009
177More on IL-21; <i>Final Phase 2 Results for IL-21 in Renal Cell Cancer ShSteve Lokness-5/15/2009
176<i>Using a mouse model of chronic viral infection, we demonstrate that intSteve Lokness-5/13/2009
175[IL-21 Is Required to Control Chronic Viral Infection.] >>Science. 2009 Mtuck-5/10/2009
174siliconinvestor.comDewDiligence_on_SI-5/5/2009
173Ah, so last quarter's beat is from inventory building during that period. Ttuck-5/5/2009
172>>ZymoGenetics Licenses Non-Core Assets to Seattle Life Sciences On Mondaytuck-5/4/2009
171>>ZymoGenetics Announces Workforce Reduction and Restructuring On Wednesdatuck-4/29/2009
170Thanks for the pointers. I haven't had time to look at the posters yet. I tuck-4/27/2009
169<i>very good data for PEG-interferon lambda</i> There are some genuDewDiligence_on_SI-4/24/2009
168Small 1b trial, but given that caveat . . . very good data for PEG-intetuck-4/24/2009
167[Recombinant Thrombin: Safety and Immunogenicity in Burn Wound Excision and Graftuck-4/9/2009
166[IL-21R P2a melanoma abstract prodies a bit more color] >> Clin Cancer Retuck-3/15/2009
165>>On March 9, 2009, ZymoGenetics, Inc. (the "Company") received tuck-3/12/2009
164Recothrom making inroads, as one would have expected from ZGEN's report; it tuck-2/27/2009
163[A review of three stand-alone topical thrombins for surgical hemostasis.] >tuck-2/27/2009
162I have the excuse, however poor, of being sleepy and wine addled -- and I had thtuck-2/12/2009
161They could’ve made life easier for us all by simply saying in the PR that the $2DewDiligence_on_SI-2/12/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News